Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Sees Portfolio As Mostly Pandemic-Resistant

But Some Trials Being Impacted

Executive Summary

Takeda says the coronavirus is affecting some of its clinical programs but that many key pipeline assets remain on track, while its existing commercial portfolio is seen as resilient by nature.

You may also be interested in...



EU Fast-Track Review In Store For Takeda’s Dengue Vaccine

Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.

APAC Podcast: Virus Industry Impact, China Vaccines, Remdesivir Deals, Korea SitRep

Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.

APAC Podcast: Virus Industry Impact, China Vaccines, Remdesivir Deals, Korea SitRep

Join the Pink Sheet and Scrip's Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel